Abstract
For patients with ALK positive non-small cell lung cancer (NSCLC), various treatment options are currently available. Crizotinib was the first drug with proven activity for these patients (1), followed by ceritinib (2,3) and alectinib (4-6) for patients progressing on crizotinib treatment. Most recently brigatinib was also approved for crizotinib-resistant patients, while lorlatinib received breakthrough status from the FDA and may be the next ALK inhibitor to be approved. These alternatives appear to be active against mutations in the ALK gene associated with crizotinib resistance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
